EP1592436A2 - Composes fixant les recepteurs p2y sb 2 /sb ou p2y sb 1 /sb - Google Patents

Composes fixant les recepteurs p2y sb 2 /sb ou p2y sb 1 /sb

Info

Publication number
EP1592436A2
EP1592436A2 EP03781372A EP03781372A EP1592436A2 EP 1592436 A2 EP1592436 A2 EP 1592436A2 EP 03781372 A EP03781372 A EP 03781372A EP 03781372 A EP03781372 A EP 03781372A EP 1592436 A2 EP1592436 A2 EP 1592436A2
Authority
EP
European Patent Office
Prior art keywords
acid
ester
xaa
composition
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03781372A
Other languages
German (de)
English (en)
Other versions
EP1592436A4 (fr
Inventor
Julie M. Villanueva
Stephen Quirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kimberly Clark Worldwide Inc
Kimberly Clark Corp
Original Assignee
Kimberly Clark Worldwide Inc
Kimberly Clark Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly Clark Worldwide Inc, Kimberly Clark Corp filed Critical Kimberly Clark Worldwide Inc
Publication of EP1592436A2 publication Critical patent/EP1592436A2/fr
Publication of EP1592436A4 publication Critical patent/EP1592436A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Definitions

  • the present invention relates to the use of compounds that can bind and modulate the activity of P2Y 2 or P2Y
  • COPD chronic obstructive pulmonary disease
  • CB chronic bronchitis
  • PCD Primary Ciliary Dyskinesia
  • Sinusitis is an inflammation of the paranasal sinuses typically associated with an upper respiratory infection. It is this country's most common health-care complaint, affecting an estimated 31 million people. (A. Moss and V. Parsons, National Center for Health Statistics, 1986: 66-7, DHHS Publication No. (PHS)86-1588 (1985)).
  • Otitis media (OM) is a viral or bacterial infection of the middle ear that primarily afflicts children under the age of three. It is usually precipitated by an upper respiratory infection that spreads into the middle ear via the nasopharynx and eustachian tube.
  • Dry eye disease is the general term for indications produced by abnormalities of the precomeal tear film characterized by a decrease in tear production or an increase in tear film evaporation, together with the ocular surface disease that results.
  • the pharmaceutical treatment of dry eye disease is mostly limited to administration of artificial tears (saline solution) to temporarily rehydrate the eyes.
  • relief is short lived and frequent dosing is necessary.
  • vaginal dryness Approximately 40% of postmenopausal women experience atrophic vaginitis or vaginal dryness. During vaginal atrophy, the vaginal epithelium decreases in thickness, hydration, ruggae (folds), and blood flow.
  • causes of atrophic vaginitis include a decrease in the amount of estrogen present both locally and systemically as well as environmental factors such as chemotherapy, antihistamines, smoking cigarettes, excessive exercise, and vaginal products (i.e. douches, deodorants, and perfumes).
  • Estrogens or hormone replacement therapies cab be effective in reducing vaginal dryness.
  • possible dangerous side effects include higher incidences of breast cancer, endometrial cancer, blood clots, nausea, breast tenderness, and headache.
  • Products that are available over-the-counter include lubricants such as Astro glide and KY Lubricating Jelly as well as moisturizers such as Replens and KY Long Lasting Moisturizer. These products, which are mostly water in composition, provide only temporary relief (1-2 days) for symptoms and provide virtually no long-term benefits to the vaginal tissue.
  • the invention provides compositions and methods for modulating mucus production from a variety of mucosal surfaces.
  • mucosal surfaces include, for example, the mucosal surfaces of the lungs, throat, sinuses, nasal passages, ear canals, eyes and female reproductive tract.
  • the invention also provides non-hormonal therapies for vaginal problems such as atrophic vaginitis.
  • non-hormonal therapies for vaginal problems such as atrophic vaginitis.
  • the benefits of these therapies include minimal side effects, perform their functions by natural mechanisms, and maintain or restore healthy reproductive tissue function.
  • the invention therefore provides a composition comprising an effective amount of peptide that can bind a P2Y 2 or P2Yj receptor and a pharmaceutically acceptable excipient, wherein the peptide comprises any one of SEQ ID NO: 1-47.
  • the invention also provides a composition comprising an effective amount of a compound that can bind a P2Y 2 or P2Y ⁇ and a pharmaceutically acceptable excipient, wherein the compound comprises P-nitrobenzyl-oxycarbonyloxy-succinimide; l-benzyl-2- 2-5-dioxotetrahydro- 1 H-pyrrol- 1 -yl-pyrrolidine- 1 -2-dicarboxylate; 5-3-methoxycarbonyl- acryloyl-isophthalic-acid-dimethyl-ester; 6-O- ⁇ -glucopyranosyl- ⁇ -D-glucose; cyclobutane- 1-2-3-4-tetracarboxylic-acid-dimethyl
  • the composition can, for example, be provided as a tablet, capsule, aerosol, solution, lotion, cream, gel, spray, inhaler, foam or vaginal insert.
  • the composition is administrated by inhalation or by use of a nebulizer.
  • composition can be used to modulate the amount, viscosity or retention of mucus by a mucosal surface.
  • the invention further provides a method for modulating the activity of a P2Y 2 or P2Y ⁇ receptor in a mucosal surface of a mammal comprising administering to the mammal a composition comprising an effective amount of a peptide or compound of the invention that can bind a P2Y 2 or P2Yj receptor and a pharmaceutically acceptable excipient.
  • the invention provides a method of preventing or treating vaginal dryness in a mammal in need of such prevention or treatment comprising administering to the vaginal cavity an effective amount of a composition comprising a peptide or compound of the invention that can bind a P2Y 2 or P2Y ⁇ receptor and a pharmaceutically acceptable excipient for use in the vaginal cavity area.
  • the invention further provides a method for treating cystic fibrosis in a mammal by modulating the activity of a P2Y 2 or P2Y ⁇ receptor in mucosal surfaces of the lung comprising administering to the mammal a composition comprising an effective amount of a peptide or compound of the invention that can bind a P2Y 2 or P2Y ⁇ receptor and a pharmaceutically acceptable excipient.
  • FIG 1 graphically illustrates the dock score profile obtained for the top 10,000 compounds in the Available Chemicals Database (version 2000.1). The insert shows the dock score profile for the top 200 compounds.
  • compositions and methods for modulating (increasing or decreasing) the secretion of mucus from mucosal surfaces of a mammal involve administering a composition comprising a compound or a peptide that can bind a P2Y 2 or P2Y ⁇ receptor.
  • peptides of the invention include a peptide of any one of SEQ ID NO:44-47.
  • a variety of compounds are provided herein that can also bind to a P2Y 2 or P2Y ⁇ receptor.
  • the compositions and methods of the invention can change the quantity and quality of the secretions of the reproductive organs and influence the activity of a P2Y 2 or P2Y ⁇ receptor. For example, increased activation of P2Y 2 or P2Y ⁇ receptor results in increases in the secretion of mucin from the cell.
  • Mucins refer to a family of glycoproteins of high molecular weight, secreted or expressed by goblet and nongoblet epithelial cells of mucosal tissues. Mucins can form mucus, a highly hydrated gel of particular structure and function. Mucins from diverse species have similar structural features, particularly with regard to the mucin protein backbone. Nine distinct mucin genes have been identified (MUC1, 2, 3, 4, MUC5AC, MUC5B, MUC6, 7 and 8). Mucins are glycoproteins containing from fifty to eighty percent carbohydrate.
  • oligosaccharide side chains or bristles
  • These molecules can be highly variable in their make-up, indicating that the more basic functions of the molecule derive from the protein core.
  • These molecules can be crosslinked through disulfide bridges to form very high molecular weight gels.
  • Different tissues may produce different types of mucins.
  • the compounds and peptides provided herein can modulate (stimulate or decrease) mucin or mucus production.
  • Influences on mucus secretion include, but are not limited to, the quantity and type of mucin (e.g. sulfomucin and/or sialomucin), changes in viscosity, hydrogen ion retardation, hydrophobicity, changes in phospholipid content, glycosylation and sulfation, macromolecular assembly, surface tension, adhesivity, transport properties, elastic modulus, tensile properties, rigidity factors, recoil factors, spinnhus, sperm penetration qualities, consistency, cellularity, ferning, and the like.
  • mucin e.g. sulfomucin and/or sialomucin
  • changes in viscosity e.g. sulfomucin and/or sialomucin
  • changes in viscosity e.g. sulfomucin and/or sialomucin
  • changes in viscosity e.g. sulfomucin and
  • the compounds and methods of the invention can modulate the secretion of mucus from any mucosal surface in a mammal.
  • the mucosal surface can be a surface of a lung, a sinus, a nasal passage, an ear canal, an eye, a throat, or a reproductive canal (e.g. a female reproductive canal).
  • the compounds and methods of the invention can change the constitutive and stimulated secretions of the local reproductive system, including those of the vagina, cervix, uterus, fallopian tube, Bartholin or vestibular glands and urethral secretions.
  • the methods and compositions of the invention can influence the function of the mucus genes found in the reproductive system, including, but not limited to genes that control mucus production in the cervix, uterus, and Bartholin's glands and other parts of the reproductive system with mucus secreting cells.
  • the squamous epithelium of the lower genital tract (vagina; for example) and epithelial cells of the cervix can be treated by the methods of the invention.
  • Mucus can be defined by its chemical, physical and biological properties.
  • Rheological or flow properties of mucus include viscosity, rate of flow, shear index, spinnhus or stretch of mucus due to increased viscoelasticity and ferning (crystallization) parameters.
  • Changing or stimulating the hydration, viscosity, quantity or other properties of vaginal secretions can influence a variety of conditions and disorders, including, but not limited to contraception, infertility, menopause, dyspareunia, infections, and others related and unrelated conditions. Description of the function and anatomy of th these organs can be found in Novak's Gynecology, 12 edition, eds. Berek, Adashi and Hillard, Williams and Wilkins, Baltimore, Md., 1996.
  • the invention therefore has at least two general utilities.
  • First, the invention may increase the amount of mucus and/or the water content of secretions from mucosal surfaces.
  • the invention may be used to decrease the amount of mucus and/or inhibit the retention of mucus in organs that typically produce mucus.
  • P2Y 2 Pathway P2Y 2 receptors are P2-purinoceptors are transmembrane receptors on epithelial cells that interact with purines, particularly with ATP and UTP.
  • P2-purinoceptors comprise two major families, P2X and P2Y. Each family consists of at least seven members (X ⁇ - 7 and Y 1 - 7 ).
  • the P2X family represents cell membrane ligand-binding ion channels permeable to Na + , K + , and Ca ⁇ " .
  • the P2Y-purinoceptors constitute G-protein-linked receptors, often coupled to phospholipase C and, hence, to inositol triphosphate formation.
  • P2Y 2 pathway can be manipulated by the methods of the invention. This pathway normally begins with the binding of nucleotide(s) or nucleoside(s) to the P2Y 2 receptor that is on or within the epithelial cell membrane. This pathway is typically linked to the activation of protein kinase C (PKC).
  • PPC protein kinase C
  • Activation of protein kinase C leads to increased levels of inositol 1,4,5-triphosphate and diacylglycerol, resulting in the influx of Ca 2+ (Garrad et al., J. Biol. Chem. 1998, 273(45), 29437-29444). Protein kinase C activation has also been shown to affect mucin secretion (Li et al., J. Biol. Chem. 2001, 276(44):40982-90). Activated protein kinase C may phosphorylate a protein called myristoylated alanine-rich C kinase substrate (MARCKS) that then migrates from the plasma membrane into the cytoplasm of epithelial cells.
  • MARCKS myristoylated alanine-rich C kinase substrate
  • the phosphorylated-MARCKS protein is dephosphorylated by protein phosphatase 2A (PP2A) in the cytoplasm, and thereby regains its capacity to bind membranes.
  • MARCKS may associate with actin and myosin and may thereby mediate the movement of mucin-containing granules to the cell periphery.
  • a series of biochemical events take place after dNTP-P2Y 2 receptor binding that eventually results in the secretion of mucin, a glycoprotein that is a component of mucus. Mucin causes a natural lubricating and moisturizing effect in the female genital tract.
  • the peptides and other compounds of the invention can activate the P2Y 2 receptor and thereby increase the production of mucus. Moreover, the peptides and other compounds of the invention can also modulate the activity of P2Y 2 receptor and thereby decrease the production or retention of mucus.
  • the peptides of the invention can bind to P2Y 2 or P2Y ⁇ receptors. Such peptides can activate or depress the activity of P2Y 2 or P2Y ⁇ receptors. Mixtures of peptides with different sequences are also contemplated for use in the compositions and methods of the invention. In general, the peptide sequences, peptide variants and mixtures of peptides are formulated and used in a manner that optimizes activation or inhibition of P2Y 2 or P2Y ⁇ receptors. Hence, the composition and formulations of the present peptides can be varied so that the desired secretion, viscosity and/or retention of mucus are achieved.
  • the size of a peptide agonist can vary. In general, a single amino acid may be too small to modulate mucus production. However, a peptide of about two amino acids may be large enough to provide optimal modulation of P2Y 2 or P2Y ⁇ receptors. Hence, peptides of about two or more amino acids are generally sufficiently long for P2Y 2 or P2Y] receptor modulation. While the overall length is not critical, peptides that are as long as or longer than about three amino acids are desirable. Other desirable peptides are longer than three amino acids. There is no particular upper limit on peptide size. However, it is generally cheaper to make shorter peptides than longer peptides. Hence, the peptide agonists of the invention are generally shorter than about one hundred amino acids. Desirable peptide modulators are often shorter than about fifty amino acids.
  • peptide modulators Each of the peptides listed in Table 1, as well as peptide having sequences like those in Formulae I-IV are useful as peptide modulators. Such peptides can have one or more amino acid substitutions, deletions, insertions or other modifications so long as the peptide variant can modulate mucus secretion or bind to a P2Y 2 or P2Y[ receptor.
  • Amino acid residues of the isolated peptides can be genetically encoded L-amino acids, naturally occurring non-genetically encoded L-amino acids, synthetic L-amino acids or D-enantiomers of any of the above.
  • the amino acid notations used herein for the twenty genetically encoded L-amino acids and common non-encoded amino acids are conventional and are as shown in Table 2.
  • Peptides that are encompassed within the scope of the invention can have one or more amino acids substituted with an amino acid of similar chemical and/or physical properties, so long as these variant peptides retain the ability to modulate mucus secretion or to bind one or more P2Y 2 or P2Yj receptors.
  • modified peptides include those listed below in Table 3.
  • amino acids that are substitutable for each other generally reside within similar classes or subclasses. As is known to one of skill in the art, amino acids can be placed into three main classes: hydrophilic amino acids, hydrophobic amino acids and cysteine-like amino acids, depending primarily on the characteristics of the amino acid side chain. These main classes may be further divided into subclasses. Hydrophilic amino acids include amino acids having acidic, basic or polar side chains and hydrophobic amino acids include amino acids having aromatic or apolar side chains. Apolar amino acids may be further subdivided to include, among others, aliphatic amino acids. The definitions of the classes of amino acids as used herein are as follows:
  • Hydrophobic Amino Acid refers to an amino acid having a side chain that is uncharged at physiological pH and that is repelled by aqueous solution.
  • genetically encoded hydrophobic amino acids include He, Leu and Val.
  • non- genetically encoded hydrophobic amino acids include t-BuA.
  • Aromatic Amino Acid refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated p-electron system (aromatic group).
  • aromatic group may be further substituted with substituent groups such as alkyl, alkenyl, alkynyl, hydroxyl, sulfonyl, nitro and amino groups, as well as others.
  • substituent groups such as alkyl, alkenyl, alkynyl, hydroxyl, sulfonyl, nitro and amino groups, as well as others.
  • Examples of genetically encoded aromatic amino acids include phenylalanine, tyrosine and tryptophan.
  • aromatic amino acids include phenylglycine, 2-naphthylalanine, ⁇ -2-thienylalanine, l,2,3,4-tetrahydroisoquinoline-3- carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine and 4-fluorophenylalanine.
  • Apolar Amino Acid refers to a hydrophobic amino acid having a side chain that is generally uncharged at physiological pH and that is not polar. Examples of genetically encoded apolar amino acids include glycine, proline and methionine. Examples of non- encoded apolar amino acids include Cha.
  • Aliphatic Amino Acid refers to an apolar amino acid having a saturated or unsaturated straight chain, branched or cyclic hydrocarbon side chain.
  • genetically encoded aliphatic amino acids include Ala, Leu, Val and He.
  • non- encoded aliphatic amino acids include Nle.
  • Hydrophilic Amino Acid refers to an amino acid having a side chain that is attracted by aqueous solution.
  • examples of genetically encoded hydrophilic amino acids include Ser and Lys.
  • examples of non-encoded hydrophilic amino acids include Cit and hCys.
  • Acidic Amino Acid refers to a hydrophilic amino acid having a side chain pK value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Examples of genetically encoded acidic amino acids include aspartic acid (aspartate) and glutamic acid (glutamate).
  • Basic Amino Acid refers to a hydrophilic amino acid having a side chain pK value of greater than 7.
  • Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion.
  • genetically encoded basic amino acids include arginine, lysine and histidine.
  • non-genetically encoded basic amino acids include the non-cyclic amino acids omithine, 2,3- diaminopropionic acid, 2,4-diaminobutyric acid and homoarginine.
  • Poly Amino Acid refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which has a bond comprising a pair of electrons shared by two atoms where the electrons are held more closely by one of the atoms.
  • genetically encoded polar amino acids include asparagine and glutamine.
  • non-genetically encoded polar amino acids include citrulline, N-acetyl lysine and methionine sulfoxide.
  • Cysteine- Like Amino Acid refers to an amino acid having a side chain capable of forming a covalent linkage with a side chain of another amino acid residue, such as a disulfide linkage.
  • cysteine-like amino acids generally have a side chain containing at least one thiol (SH) group.
  • examples of genetically encoded cysteine-like amino acids include cysteine.
  • examples of non-genetically encoded cysteine-like amino acids include homocysteine and penicillamine.
  • cysteine has both an aromatic ring and a polar hydroxyl group.
  • cysteine has dual properties and can be included in both the aromatic and polar categories.
  • cysteine also has apolar character.
  • cysteine can be used to confer hydrophobicity to a peptide.
  • Certain commonly encountered amino acids that are not genetically encoded and that can be present, or substituted for an amino acid, in the peptides and peptide analogs and derivatives of the invention include, but are not limited to, ⁇ -alanine (b-Ala) and omega-amino acids such as 3-aminopropionic acid (Dap), 2,3-diaminopropionic acid (Dpr), 4-aminobutyric acid and so forth; a-aminoisobutyric acid (Aib); e-aminohexanoic acid (Aha); d-aminovaleric acid (Ava); methylglycine (MeGly); ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA); t-butylglycine (t-BuG); N-methylisoleucine (Melle); phenylglycine (Phg); cyclohexylalanine (Cha); norleu
  • Table 4 The classifications of the above-described genetically encoded and non-encoded amino acids are summarized in Table 4 below. It is to be understood that Table 4 is for illustrative purposes only and does not purport to be an exhaustive list of amino acid residues that may comprise the peptides and peptide analogues described herein. Other amino acid residues that are useful for making the peptides and peptide analogues described herein can be found, e.g., in Fasman, 1989, CRC Practical Handbook of Biochemistry and Molecular Biology, CRC Press, Inc., and the references cited therein. Amino acids not specifically mentioned herein can be conveniently classified into the above-described categories on the basis of known behavior and/or their characteristic chemical and/or physical properties as compared with amino acids specifically identified.
  • Peptides of the invention can have any amino acid substituted by any similarly classified amino acid to create a variant peptide, so long as the peptide variant retains an ability to modulate mucus production or to bind one or more P2Y 2 or P2Y ⁇ receptors.
  • Peptides of the invention can also have one or more amino acids replaced by a dissimilarly charged amino acid to generate a peptide derivative that has desirable properties in addition to binding one or more P2Y 2 or P2Y ( receptors, for example, enhanced stability, enhanced mucus secretion or enhanced activation of P2Y 2 or P2Y ⁇ receptors.
  • a variety of peptides can therefore bind P2Y 2 or P2Y ⁇ receptors, including peptides having any one of SEQ ID NO:44-47.
  • SEQ ID NO:44 encompasses the following peptides.
  • Xaa 2 is an aliphatic amino acid
  • Xaa 3 , Xaa ⁇ s are separately each a basic amino acid
  • Xaa-*, Xaa 8 are separately each an apolar amino acid
  • Xaa is an acidic amino acid
  • Xaa 7 and Xaa 9 are separately each an aromatic amino acid
  • Xaaio and Xaa ⁇ are separately each a polar amino acid; wherein the peptide is capable of binding to a P2Y 2 or P2Y ⁇ receptor. Such binding may increase P2Y 2 receptor activity and/or increase the production of mucus.
  • SEQ ID NO:45 is directed to peptides of the following structure.
  • aa , X ai 6 , Xaa ⁇ 9 , Xaa 23 , Xaa 24 , and aa3o are separately each a polar amino acid;
  • Xaa ⁇ , Xaais, Xaa 25 , Xaa 28, Xaa33 and Xaa 34 are separately each an aliphatic amino acid;
  • Xaa ⁇ 4 , Xaai 7 , Xaa 2 ⁇ , Xaa 26 and Xaa 3 ⁇ are separately each a basic amino acid;
  • Xaa ⁇ is an apolar amino acid;
  • Xaa 2 o is a cysteine-like amino acid;
  • Xaa 22 and Xaa 27 are separately each an acidic amino acid; Xaa 29 and Xaa 32 are separately each an aromatic amino acid; and Xaa 35 is an aromatic or polar amino acid; wherein the peptide is capable of binding to a P2Y 2 or P2Y ⁇ receptor. Such binding may increase P2 Y 2 receptor activity and/or increase the production of mucus.
  • SEQ ID NO:46 is directed to peptides of the following structure.
  • Xaa 3 6, Xaa43, Xaa- 4 , Xaa 49; Xaa 50 , Xaa52, Xaa 53 , Xaa 5 6 and Xaa 9 are separately each an aliphatic amino acid;
  • Xaa 37 , Xaa 38 , and Xaa 57 are separately each an aromatic or polar amino acid;
  • Xaa 3 , Xaa- ⁇ , Xaa 46 , Xaa4 , Xaa 5 ⁇ , Xaa 54 and Xaa ⁇ are separately each a polar amino acid;
  • Xaa- t o is an aromatic amino acid
  • X a 4 i, Xaajs, Xaa 58 and Xa-- 6 i are separately each a basic amino acid;
  • Xaa-n is an acidic amino acid;
  • Xaa 4 is a cysteine-like amino acid;
  • Xaa 55 is an apolar amino acid; wherein the peptide is capable of binding to a P2Y2 or P2Yj receptor. Such binding may increase P2Y 2 receptor activity and/or increase the production of mucus.
  • SEQ ID NO:47 is directed to peptides of the following structure.
  • Xaa62, Xaa 63 , Xaa ⁇ , Xaa 66 ,Xaa 73 , Xaa 79 , Xaa 82 , Xaa 95 and Xaa 96 are separately each an aliphatic amino acid;
  • Xaa 65 , Xaa 67, Xaa 78 , Xaa 80 , Xaa 8 ⁇ , Xaa 90 and Xaa 9 ⁇ are separately each an acidic amino acid;
  • Xaa 6 8 is an apolar amino acid
  • X a 6 , Xaa 77 , Xaa g8 and Xaa 2 are separately each an aromatic amino acid;
  • Xaa 7 o, Xaa 7 ⁇ , Xaa 72 , Xaa 74 , Xaa 76 and Xaa 8 are separately each a polar amino acid;
  • Xaa 75 , Xaa 83 and Xaa 86 are a cysteine-like amino acid
  • Xaa 8 and Xaa are separately each an aromatic or polar amino acid
  • Xaa 85 , Xaa 87 and Xaa 3 are separately each a basic amino acid; wherein the peptide is capable of binding to a P2Y2 or P2Y ⁇ receptor. Such binding may increase P2Y 2 receptor activity and/or increase the production of mucus.
  • Compounds that can bind to P2Y 2 or P2Y ⁇ receptors are of the appropriate size and hydrophobicity or charge distribution to optimally occupy a P2Y 2 or P2Y ⁇ receptor site.
  • To ascertain whether a compound can bind to a P2Y2 or P2Y t receptor site the coordinates, hydrophobicity and charge of atoms within a P2Y 2 or P2Y ⁇ receptor site can be mapped and computer searches can be performed to ascertain whether a test compound can appropriately interact or bind within a site of that size, hydrophobicity or charge.
  • test compounds can be screened for binding to a P2Y2 or P2Yt receptor site using the program suite LigandFit from MSI, Inc.
  • Crystal structures of a P2Y 2 or P2Y ⁇ receptor site that are available to one of skill in the art can be used as a source of protein atomic coordinates for a P2Y 2 or P2Y ⁇ receptor site.
  • one such search yielded about two hundred compounds, when using the chick P2Y ⁇ purinoceptor complexed with adenosine triphosphate (PDB code 1DDD) as the source of protein atomic coordinates.
  • PDB code 1DDD adenosine triphosphate
  • Examples of compounds that can bind to a P2Y 2 or P2Y ⁇ receptor include P- nitrobenzyl-oxycarbonyloxy-succinimide, 1 -benzyl -2-2-5-dioxotetrahydro- 1 H-pyrrol- 1 -yl- pyrrolidine- 1 -2-dicarboxylate, 5-3-methoxycarbonyl-acryloyl-isophthalic-acid-dimethyl- ester, Gentiobiose ( ⁇ -gentiobiose, which is 6-O- ⁇ -glucopyranosyl- ⁇ -D-glucose, can be purchased from Sigma Chemical Company), Cyclobutane-l-2-3-4-tetracarboxylic-acid- dimethyl-ester, Mono-2-acryloyloxyethyl-succinate, 2-benzyloxycarbonylamino-3-methyl- butyric-acid-2-5-dioxo-pyrrolidin-l -yl-est
  • the present invention is directed to a variety of methods of treating or preventing dryness or mucosal build-up in organs having mucosal surfaces.
  • the peptides and compounds of the present invention can bind P2Y2 and/or P2Y ⁇ purinergic receptors.
  • These compounds and peptides are useful in the treatment of mammals including humans suffering from chronic obstructive pulmonary diseases such as chronic bronchitis, Primary Ciliary Dyskinesia, cystic fibrosis, as well as prevention of pneumonia. Furthermore, because of their general ability to clear retained mucus secretions, the compounds of the present invention are also useful in the treatment of sinusitis, otitis media and nasolacrimal duct obstruction in mammals. Additionally, the compounds of the present invention are useful for treating mammals with dry eye, vaginal and/or reproductive problems in a female mammal, vaginal dryness and retinal detachment.
  • the compounds of the present invention are primarily concerned with the treatment of human subjects, they may also be employed for the treatment of other mammalian subjects such as dogs and cats for veterinary purposes.
  • mammal refers to an animal, in general, a warm-blooded animal. Mammals include cattle, buffalo, sheep, goats, pigs, horses, dogs, cats, rats, rabbits, mice, and humans. Also included are other livestock, domesticated animals and captive animals.
  • Treatment of, or treating, a mammal is intended to include modulation of mucus levels to enhance or diminish mucus production in the mammal.
  • such treatment involves alleviating or diminishing the symptoms of cystic fibrosis, pneumonia, vaginal dryness, or chronic obstructive pulmonary diseases such as chronic bronchitis or Primary Ciliary Dyskinesia in a mammal.
  • the treatment therefore can include alleviation or diminishment of more than one problem associated with mucus secretion in a mammal.
  • the method increases secretion of mucus in vaginal or cervical epithelial cells.
  • the method involves activating P2Y 2 or P2Y ⁇ receptors in vaginal or cervical cells. Such methods can prevent or treat vaginal dryness in a mammal, or maintain or enhance the normal protective function of vaginal mucus in a mammal.
  • Treatment involves administering an effective amount of a compound or peptide of the invention to a mammal.
  • the peptides and/or compounds may be administered as a composition that contains other ingredients.
  • the uterine cervix plays a critical role in reproduction.
  • the following functions can be attributed to vaginal/cervical mucus and its role in reproduction: 1) Semen is filtered at the cervical os and sperm allowed entry into the uterus from a relatively hostile vaginal environment; 2) Sperm are nurtured within the cervical canal and supported and prepared for capacitation; 3) Sperm are stored and later released in order to co-ordinate with ovulation. Katz, D. F. Human Cervical Mucous: Research Update. Am. J. Obstet. Gynecol. 1991 :165: 1984-6.
  • Cervical mucus is a mixture of mucin secreted by the mucus cells and transudation of capillary exudates, which include water (85-98%), electrolytes, serum and locally derived proteins.
  • the mucins are responsible for the rheological properties of mucus, but comprise less than 1% in volume. Apparently, during the mid-cycle, estrogens stimulate the stromal cells, which in turn stimulate the mucus cells. The mucus produced during this time has a higher water content, which accounts for part of the rheological changes such as ferning.
  • the human cervix secretes a profuse, clear and thin mucus, at a rate of about 600 mg of mucus a day, in the pre-ovulatory and ovulatory phases of the menstrual cycle. Under the influence of progestins, this rate decreases to 20-60 mg/day and the mucus is thick and viscous. Moghissi, K S. The function of the cervix infertility. Fert. Steril. 1972 23:295-306.
  • compositions of the invention are administered to improve the health of mucosal surfaces, to stimulate secretion of lubricating fluids and/or to reduce retention of viscous fluids in organs that normally have mucosal surfaces.
  • a composition of the invention comprises an effective amount of a compound or peptide of the invention and a pharmaceutically acceptable carrier. Mixtures of compounds and/or peptides can also be administered.
  • the composition may be administered as single or divided dosages, for example, of at least about 0.001 ⁇ g to about 100 to 200 mg peptide or compound per kilogram of body weight, of about 0.01 ⁇ g to about 30 to 50 mg peptide or compound per kilogram of body weight, about 1.0 ⁇ g to about 10 to 20 mg peptide or compound per kilogram of body weight or about 10 ⁇ g to about 1.0 to about 10 mg peptide or compound per kilogram of body weight, although other dosages may provide beneficial results.
  • the amount administered will vary depending on various factors including, but not limited to, the disease, the weight, the physical condition, the health, the age of the mammal, and whether prevention of reproduction or treatment of vaginal dryness is to be achieved. Such factors can be readily determined by the clinician employing animal models or other test systems that are available in the art.
  • Administration of the therapeutic agents in accordance with the present invention may be in a single dose, in multiple doses, in a continuous or intermittent manner, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
  • the administration of the compositions of the invention may be essentially continuous over a pre-selected period of time or may be in a series of spaced doses. Local administration is generally contemplated.
  • compositions are prepared by combining the active ingredients in the appropriate concentrations.
  • Other active or inactive agents selected by one of skill in the art can optionally be added.
  • the absolute weight of a given active agent included in a unit dose can vary widely. For example, about 0.001 ⁇ g to about 50 mg, or about 0.01 ⁇ g to about 10 mg, or about 0.1 ⁇ g to about 1 mg, of at least one peptide or compound of the invention can be administered.
  • the unit dosage can vary from about 0.001 ⁇ g to about 1000 ⁇ g, from about 0.01 ⁇ g to about 750 ⁇ g, from about 0.1 ⁇ g to about 1 mg, from about 1.0 ⁇ g to about 750 ⁇ g, from about 2.5 ⁇ g to about 600 ⁇ g, from about 5.0 ⁇ g to about 500 ⁇ g, or from about 7.5 ⁇ g to about 400 ⁇ g of at least one peptide or compound of the invention .
  • Daily doses of the compositions of the invention can vary as well. Such daily doses can range, for example, from about 0.001 mg/day to about 50 mg/day, from about 0.01 mg/day to about 25 mg/day, from about 0.1 mg/day to about 12 mg/day, from about 0.1 mg/day to about 8 mg/day, from about 0.1 mg/day to about 4 mg/day, and from about 0.1 mg/day to about 2 mg/day of at least one peptide or compound of the invention.
  • one or more suitable unit dosage forms comprising the therapeutic compositions of the invention can be administered by a variety of routes including oral, parenteral (including subcutaneous, intravenous, intramuscular and intraperitoneal), rectal, dermal, transdermal, intrathoracic, intrapulmonary intravaginal and intranasal (respiratory) routes.
  • the therapeutic compositions may also be formulated for sustained release (for example, using microencapsulation, see WO 94/ 07529, and U.S. Patent No.4,962,091).
  • the formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known to the pharmaceutical arts. Such methods may include the step of mixing the therapeutic agent with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping the product into the desired delivery system.
  • compositions of the invention are prepared for intravaginal administration, they are generally combined with a pharmaceutically acceptable carrier, diluent or excipient to form a pharmaceutical formulation, or unit dosage form.
  • a pharmaceutically acceptable carrier diluent or excipient to form a pharmaceutical formulation, or unit dosage form.
  • the compositions may be present as a solution, a suspension, an emulsion, a powder, a granular formulation, or in a natural or synthetic polymer or resin.
  • the active compositions may also be presented as a bolus or paste.
  • Intravaginally administered peptides or compounds of the invention can also be formulated for sustained release, e.g., the peptides or compounds can be coated, micro-encapsulated, or otherwise placed within a sustained delivery device.
  • the total active ingredients in such formulations comprise from 0.1 to 99.9% by weight of the formulation.
  • pharmaceutically acceptable means a carrier, diluent, excipient, and/or salt is compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
  • compositions containing the therapeutic compositions of the invention can be prepared by procedures known in the art using well-known and readily available ingredients.
  • the composition can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, lotions, solutions, suspensions, powders, aerosols, creams and the like.
  • excipients, diluents, and carriers that are suitable for such formulations include buffers, as well as fillers and extenders such as starch, cellulose, sugars, mannitol, and silicic derivatives.
  • Binding agents can also be included such as carboxymethyl cellulose, hydroxymethylcellulose, hydroxypropyl methylcellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone.
  • Moisturizing agents can be included such as glycerol, disintegrating agents such as calcium carbonate and sodium bicarbonate.
  • Agents for retarding dissolution can also be included such as paraffin.
  • Reso ⁇ tion accelerators such as quaternary ammonium compounds can also be included.
  • Surface-active agents such as cetyl alcohol and glycerol monostearate can be included.
  • Adso ⁇ tive carriers such as kaolin and bentonite can be added.
  • Lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols can also be included. Preservatives may also be added.
  • the compositions of the invention can also contain thickening agents such as cellulose and/or cellulose derivatives. They may also contain gums such as xanthan, guar or carbo gum or gum arabic, or alternatively polyethylene glycols, bentones and montmorillonites, and the like.
  • the therapeutic compositions of the invention can also be formulated as emulsions, suspensions, aqueous or anhydrous solutions or dispersions, or alternatively the form of an emulsion or suspension or salve for convenient intravaginal administration.
  • the active compositions and other ingredients may form suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and or dispersing agents.
  • the active compositions and other ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
  • formulations can contain pharmaceutically acceptable carriers, vehicles and adjuvants that are well known in the art. It is possible, for example, to prepare solutions using one or more organic solvent(s) that is/are acceptable from the physiological standpoint, chosen, in addition to water, from solvents such as acetone, ethanol, isopropyl alcohol, glycol ethers such as the products sold under the name "Dowanol,” polyglycols and polyethylene glycols, C1-C4 alkyl esters of short-chain acids, ethyl or isopropyl lactate, fatty acid triglycerides such as the products marketed under the name "Miglyol,” isopropyl myristate, animal, mineral and vegetable oils and polysiloxanes.
  • organic solvent(s) that is/are acceptable from the physiological standpoint, chosen, in addition to water, from solvents such as acetone, ethanol, isopropyl alcohol, glycol ethers such as the products sold under the name "Dowanol,” polygly
  • compositions are well suited to formulation as sustained release dosage forms and the like.
  • the formulations can be so constituted that they release the peptides and other active ingredients within or onto a mucosal surface over a period of time.
  • Coatings, envelopes, and protective matrices may be made, for example, from polymeric substances, such as polylactide-glycolates, liposomes, microemulsions, microparticles, nanoparticles, or waxes.
  • the therapeutic agents may be formulated as is known in the art for direct application to the vaginal area.
  • Forms chiefly conditioned for vaginal application take the form, for example, of milks, gels, dispersions, microemulsions, lotions thickened to a greater or lesser extent, impregnated pads, ointments, aerosol formulations (e.g., sprays or foams), creams, pastes, jellies, sprays, and aerosols.
  • composition can be formulated to be part of an adhesive polymer, such as polyacrylate or acrylate/vinyl acetate copolymer.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Liquid sprays are conveniently delivered from pressurized packs, for example, via a specially shaped container or applicator.
  • the active compositions can also be delivered via iontophoresis, e.g., as disclosed in U.S. Patent Nos. 4,140,122; 4,383,529; or 4,051 ,842.
  • the percent by weight of a therapeutic agent of the invention present in a formulation will depend on various factors, but generally will be from 0.01% to 95% of the total weight of the formulation, and typically 0.1-85% by weight.
  • the pharmaceutical formulations of the present invention may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, solubilizing or emulsifying agents, and salts of the type that are available in the art.
  • pharmaceutically acceptable carriers such as physiologically buffered saline solutions and water.
  • diluents such as phosphate buffered saline solutions pH 7.0-8.0.
  • active ingredients may also be used in combination with other therapeutic agents, for example, anti-microbial agents, anti-fungal agents, anti-yeast agents and the like, whether for the conditions described or some other condition.
  • the present invention further pertains to a packaged composition for controlling reproduction and/or vaginal dryness that is provided in a kit or other container.
  • the kit or container holds a therapeutically effective amount of the composition for controlling reproduction and/or vaginal dryness and instructions for using the composition for promoting reproductive health, controlling reproduction and/or preventing vaginal dryness.
  • the composition includes a compound or peptide of the present invention, in a therapeutically effective amount such that reproductive health, vaginal dryness or reproduction is controlled.
  • the docking run was conducted with full electrostatics. For each molecule the docking run was allowed to save up to 1000 possible solutions, which were then automatically clustered into groups. A group was defined by a root mean squared (rms) deviation of less than or equal to 0.3 A. The clusters were then scored based on the calculated intermolecular energy of the solution. A single top solution was saved to disk. The top 10,000 scoring unique compounds were redocked into the grid area using a combined quantum mechanical, molecular mechanics routine that allowed movement of amino acid side chains that were within 3 A of the ligand. The final scoring function is shown in Figure 1.
  • Novel P2 Y2 purinoceptor binding compounds are presented in Tables 5, 6 and 7 along with their respective dock scores (higher numbers are better).
  • Three classes of compounds were identified: peptides, modified peptides, and small organic molecules.
  • Table 6 High scoring modified peptide-based P2Y 2 receptor binding agents.
  • Table 7 High scoring small molecule P2Y 2 receptor binding agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des peptides et des composés pouvant se fixer aux récepteurs P2Y2 lesquels sont utiles pour moduler la sécrétion de mucus à l'intérieur des muqueuses.
EP03781372A 2002-12-16 2003-10-22 Composes fixant les recepteurs p2y sb 2 /sb ou p2y sb 1 /sb Withdrawn EP1592436A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US320731 1994-10-07
US10/320,731 US7056889B2 (en) 2002-12-16 2002-12-16 Compounds that bind P2Y2 or P2Y1 receptors
PCT/US2003/033658 WO2004060907A2 (fr) 2002-12-16 2003-10-22 Composes fixant les recepteurs p2y2 ou p2y1

Publications (2)

Publication Number Publication Date
EP1592436A2 true EP1592436A2 (fr) 2005-11-09
EP1592436A4 EP1592436A4 (fr) 2009-09-02

Family

ID=32506930

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03781372A Withdrawn EP1592436A4 (fr) 2002-12-16 2003-10-22 Composes fixant les recepteurs p2y sb 2 /sb ou p2y sb 1 /sb

Country Status (8)

Country Link
US (1) US7056889B2 (fr)
EP (1) EP1592436A4 (fr)
KR (1) KR101057916B1 (fr)
CN (1) CN1720061A (fr)
AU (1) AU2003287193A1 (fr)
CA (1) CA2508127A1 (fr)
MX (1) MXPA05005840A (fr)
WO (1) WO2004060907A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079830A1 (fr) * 2004-02-23 2005-09-01 Paul Fraser Inhibiteurs de la formation de fibrilles amyloides, et leur utilisation
DE102004060041A1 (de) * 2004-12-14 2006-06-29 Sanofi-Aventis Deutschland Gmbh Verwendung von substituierten Cyclopropansäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
ATE499370T1 (de) 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
ES2352796T3 (es) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
CN101321801A (zh) 2005-10-07 2008-12-10 住友化学株式会社 共聚物和使用该共聚物的高分子发光元件
EP1959968A2 (fr) * 2005-12-06 2008-08-27 P2-Science APS Modulation de la voie des recepteurs p2y2
KR101728180B1 (ko) * 2009-04-22 2017-04-18 액테리온 파마슈티칼 리미티드 티아졸 유도체들 및 ｐ2ｙ12 수용체 길항제로서 이들의 용도
US9234023B2 (en) * 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
SG11201804902UA (en) * 2015-12-21 2018-07-30 Brainon Inc A composition for improving memory, learning ability, and cognitive ability
KR101706296B1 (ko) * 2015-12-21 2017-02-13 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물
EP3681900A4 (fr) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Peptides d'agoniste opioïde et leurs utilisations
DE102019104543A1 (de) * 2019-02-22 2020-08-27 Johann Wolfgang Goethe-Universität Hybride Silikonbausteine, Verfahren zu deren Herstellung und Verwendung derselben

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043711A1 (fr) * 1998-02-27 1999-09-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antagonistes des recepteurs couples a la proteine g
WO1999055901A2 (fr) * 1998-04-30 1999-11-04 Abbott Laboratories Technique de criblage fonctionnel de grande capacite servant a identifier des ligands de purinorecepteurs humains
WO2000030629A2 (fr) * 1998-11-25 2000-06-02 Inspire Pharmaceuticals, Inc. Methode stimulant les secretions cervicales et vaginales
WO2002004955A2 (fr) * 2000-07-07 2002-01-17 University Of North Carolina At Chapel Hill Procede et systeme de dosage pour l'identification d'agonistes et d'antagonistes du recepteur p2y

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504339D0 (en) * 1995-03-03 1995-04-19 British Tech Group Free radical scavenger molecules
US5837861A (en) 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US20030176358A1 (en) * 1997-03-30 2003-09-18 Mariko Egawa Method of treating environmental stress
SE9701219D0 (sv) 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
SE9702651D0 (sv) 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
SE9702794D0 (sv) 1997-07-24 1997-07-24 Astra Pharma Prod New compounds
US6475360B1 (en) 1998-03-12 2002-11-05 Lifescan, Inc. Heated electrochemical cell
US6264975B1 (en) 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
EP1023836A1 (fr) * 1999-01-26 2000-08-02 Unilever N.V. Compositions et procédés pour inhiber la croissance des champignons
US6331529B1 (en) 1999-02-26 2001-12-18 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
EP1151745A1 (fr) * 2000-05-05 2001-11-07 L'oreal Composition sous forme d'émulsion eau-dans-huile et ses utilisations cosmétiques
US6444115B1 (en) 2000-07-14 2002-09-03 Lifescan, Inc. Electrochemical method for measuring chemical reaction rates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043711A1 (fr) * 1998-02-27 1999-09-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antagonistes des recepteurs couples a la proteine g
WO1999055901A2 (fr) * 1998-04-30 1999-11-04 Abbott Laboratories Technique de criblage fonctionnel de grande capacite servant a identifier des ligands de purinorecepteurs humains
WO2000030629A2 (fr) * 1998-11-25 2000-06-02 Inspire Pharmaceuticals, Inc. Methode stimulant les secretions cervicales et vaginales
WO2002004955A2 (fr) * 2000-07-07 2002-01-17 University Of North Carolina At Chapel Hill Procede et systeme de dosage pour l'identification d'agonistes et d'antagonistes du recepteur p2y

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JARLEBARK LEIF ET AL: "Peptidyl conjugates of adenosine 5'-carboxylic acid synthesized and evaluated as ligands for P2 purinoceptors" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 229, no. 2, 1996, pages 363-369, XP002536631 ISSN: 0006-291X *
KUEGELGEN VON I ET AL: "Molecular pharmacology of P2Y-receptors" NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 362, no. 4-5, 1 November 2000 (2000-11-01), pages 310-323, XP002199630 ISSN: 0028-1298 *
MÜLLER C E: "P2-pyrimidinergic receptors and their ligands" CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 8, no. 26, 1 January 2002 (2002-01-01), pages 2353-2369, XP008108325 ISSN: 1381-6128 *
See also references of WO2004060907A2 *
SHAVER S R: "P2Y receptors: biological advances and therapeutic opportunities" CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 4, no. 5, 1 September 2001 (2001-09-01), pages 665-670, XP008108326 ISSN: 1367-6733 *
VAN RHEE A M ET AL: "Modelling the P2Y purinoceptor using rhodopsin as template" DRUG DESIGN AND DISCOVERY, HARWOOD ACADEMIC PUBLISHERS GMBH, XX, vol. 13, no. 2, 1 November 1995 (1995-11-01), pages 133-154, XP008108241 ISSN: 1055-9612 *
VENKATACHALAM C M ET AL: "LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites." JOURNAL OF MOLECULAR GRAPHICS & MODELLING JAN 2003, [Online] vol. 21, no. 4, January 2003 (2003-01), pages 289-307, XP002536626 ISSN: 1093-3263 *

Also Published As

Publication number Publication date
CN1720061A (zh) 2006-01-11
EP1592436A4 (fr) 2009-09-02
AU2003287193A1 (en) 2004-07-29
KR101057916B1 (ko) 2011-08-19
MXPA05005840A (es) 2005-08-29
US20040116339A1 (en) 2004-06-17
KR20050089152A (ko) 2005-09-07
US7056889B2 (en) 2006-06-06
CA2508127A1 (fr) 2004-07-22
WO2004060907A3 (fr) 2004-11-25
WO2004060907A2 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
AU2003287005B2 (en) Vaginal health products
US6331529B1 (en) Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
JP5118633B2 (ja) 医療用デバイスおよび医薬製剤において有用な粘膜付着性キシログルカン含有製剤
US7056889B2 (en) Compounds that bind P2Y2 or P2Y1 receptors
US6294188B1 (en) Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
WO2002022128A1 (fr) Methode d&#39;anesthesie et d&#39;analgesie locales
US20220387547A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
US10688113B2 (en) Methods of treating eye pain with aminophosphinic derivatives
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
US20180344696A1 (en) Synergistic combination of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof, for use in the treatment and/or prevention of dryness and irritation of the mucosae, and related pharmaceutical formulations
WO2010107069A1 (fr) Composition ophtalmique contenant des acides aminés
RU2733392C1 (ru) Комбинированное офтальмологическое средство
WO2020128616A2 (fr) Procédés et compositions pour contrôler la migration et la prolifération cellulaires
KR20230014701A (ko) 바이러스 결막염의 치료
EP1191928A1 (fr) Methodes de modification des secretions constitutives et stimulees de l&#39;appareil reproducteur local de la femme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050602

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101ALI20090723BHEP

Ipc: A61K 38/16 20060101ALI20090723BHEP

Ipc: A61K 38/04 20060101AFI20041203BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090804

17Q First examination report despatched

Effective date: 20091202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100413